Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "nonalcoholic"


10 mentions found


Dec 19 (Reuters) - Madrigal Pharmaceuticals' (MDGL.O) experimental drug for fatty liver disease met both of the main goals in a highly anticipated late-stage study, it said on Monday, sending the company's shares soaring over 200%. The positive data sets the stage for the drug, resmetirom, to become the first approved treatment for NASH, or nonalcoholic steatohepatitis, a disease that affects about 5% of adults in the United States. Data from the trial shows a lower 80 milligram dose helped 26% of patients reach NASH resolution, compared to 30% for a higher 100 milligram dose, and 10% for placebo. NASH is a form of nonalcoholic fatty liver disease, characterized by the organ developing fibrosis or scarring, which can progress to cirrhosis and liver failure. The company plans to file a marketing application seeking accelerated approval for the drug in the first half of 2023.
Madrigal Pharmaceuticals reported positive results in its phase 3 trial for a drug to treat NASH. NASH is a serious liver condition that does not have an FDA-approved treatment. Many people don't even know they have it, which is why some people call it a "silent" disease. In a trial of more than 950 patients, 26% of patients taking 80mg and 30% of patients taking 100mg of the drug showed that NASH activity like swelling had been reduced. Pharma hasn't found a way to treat NASH yetThe pharma industry has been watching NASH for a while.
5 tips for taming travel tension over the holidays
  + stars: | 2022-11-17 | by ( Dana Santas | ) edition.cnn.com   time to read: +7 min
So, whether you’re driving to Grandma’s for Thanksgiving or flying to see family in another country, try the five tips below to reduce stress and tension so you can enjoy the holidays. Holiday travel can cause tension, but you can ease stress with strategies like mindful breathing and walking breaks. Stretch out the tensionLots of sitting during travel also means compressed side waist muscles, overused hip flexors and tight low-back muscles. In addition to changing your relationship with gravity to relieve tension, it’s important to get enough sleep. Using the five tips above will help keep travel tension at bay and your holiday spirits high.
But clients may not know that Freedman, 58, was accused of sexual assault in the 1980s and paid a $40,000 settlement to the accuser. She said that instead of taking her there, the men brought her to the nearby Zeta Beta Tau fraternity. The plaintiff said she and her friend then returned to Zeta Beta Tau to retrieve her shoe and car key. The 17-year-old and her parents sued Freedman and the two other fraternity brothers, as well as Zeta Beta Tau and Tau Kappa Epsilon. (Zeta Beta Tau and the other college students accused of sexual assault also agreed to pay settlements, none of which admitted liability.)
The investment gives Keurig a minority position in the beverage startup, which controls over half of the $328.6 million nonalcoholic-beer market. He quit his position at Point72 Asset Management in 2017 and cofounded Athletic Brewing a year later with the head brewer John Walker. Athletic Brewing now controls 45% of the non-alcoholic craft beer market. Athletic Brewing said it distinguishes itself from big beer brewers by being the only brewery in the country dedicated solely to nonalcoholic craft beer. The restaurateur Danny Meyer and Chang serve Athletic Brewing in Eleven Madison Park, Gramercy Tavern, The Modern, and Momofuku Ko.
Keurig Dr Pepper Inc. hired a new executive to lead its finances after it promoted its former chief financial officer to the role of chief executive. In his new role, Mr. Priyadarshi will oversee Keurig Dr Pepper’s finance and information technology divisions. Keurig Dr Pepper is scheduled to report quarterly results on Thursday. Keurig Dr Pepper has said that acquisitions are a top priority for capital allocation. Keurig Dr Pepper Monday said Mr. Priyadarshi wasn’t available for an interview and declined to comment beyond its release.
Boston Beer has an average analyst rating of hold and 8% downside to the average price target, according to FactSet. "In a recession, beer tends to gain about one percentage point of share from spirits. How to play the space With that mindset, you shouldn't alter your long-term investments because of a potential recession, Sarwat said. Its average price target is buy. Duckhorn also has an average rating of buy, with 30% upside to the average price target.
Food stamps restrict shoppers to nonalcoholic beverages, cold food items, seeds and plants. Expanding payment options for low-income shoppers could help the delivery platforms lure low-income grocery shoppers away from Walmart.com WMT.N and Amazon.com , which also have food stamp payment options. Shipt shoppers will also be able to pay for orders with SNAP EBT in 2023. Target.com customers can make grocery purchases online with SNAP EBT and their deliveries are powered by Shipt. Shipt does not currently offer any WIC or TANF payment options.
DTC delivery startup FastAF offers rapid delivery of Shopify brands. The startup FastAF has discovered a secret weapon in surviving the volatile ultrafast-delivery space: Shopify stores. On Wednesday, FastAF added nationwide shipping, allowing shoppers to bundle items into one delivery in any market in the US. at a higher cost," Hnetinka told Insider this week. "It's really put us in a position of strength compared to the other guys who've got commoditized and undifferentiated products," Hnetinka said.
A Chronic Disease Still Waiting for a Drug
  + stars: | 2022-09-20 | by ( David Wainer | ) www.wsj.com   time to read: +1 min
Drug companies have developed treatments for some of the rarest diseases afflicting a tiny percentage of the population, yet they have failed repeatedly to get a drug on the market for a chronic and increasingly common one. As biotech companies take new shots on goal for the liver disease known as NASH, or nonalcoholic steatohepatitis, investors are understandably reluctant after being burned repeatedly. Take Intercept Pharmaceuticals which at the height of the Wall Street excitement over NASH treatments fetched as much as $462 a share. The stock has since plunged, trading now at just over $17, erasing $6 billion in market value. The biotech’s drug for NASH was rejected by the U.S. Food and Drug Administration in 2020 because of safety concerns, but Intercept is trying again.
Total: 10